Dnca Finance Lowers Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Dnca Finance cut its stake in Thermo Fisher by 72.3% in Q3, selling 15,150 shares and leaving 5,800 shares valued at about $2.813 million.
• Thermo Fisher beat estimates in its latest quarter with EPS of $6.57 vs. $6.45 expected and revenue of $12.22 billion, up 7.2% year-over-year.
• The company increased its quarterly dividend to $0.47 (annualized $1.88, yield 0.4%), while institutional holders own 89.23% of the stock and analysts show a “Moderate Buy” consensus with an average target of $633.68.

Dnca Finance lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 72.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,800 shares of the medical research company's stock after selling 15,150 shares during the period. Dnca Finance's holdings in Thermo Fisher Scientific were worth $2,813,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of TMO. Vanguard Group Inc. lifted its position in shares of Thermo Fisher Scientific by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 33,789,164 shares of the medical research company's stock valued at $13,700,154,000 after buying an additional 309,207 shares in the last quarter. Capital World Investors increased its holdings in Thermo Fisher Scientific by 7.4% in the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company's stock worth $4,988,132,000 after acquiring an additional 706,572 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Thermo Fisher Scientific by 21.0% in the third quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company's stock worth $2,874,069,000 after acquiring an additional 1,028,125 shares during the last quarter. Norges Bank acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at $2,264,615,000. Finally, Bank of New York Mellon Corp lifted its holdings in Thermo Fisher Scientific by 54.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company's stock valued at $1,732,422,000 after purchasing an additional 1,262,967 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $463.99 on Friday. The company's 50 day simple moving average is $557.83 and its 200-day simple moving average is $548.17. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99. The company has a market capitalization of $172.36 billion, a price-to-earnings ratio of 26.15, a price-to-earnings-growth ratio of 2.75 and a beta of 0.96.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, topping analysts' consensus estimates of $6.45 by $0.12. The firm had revenue of $12.22 billion during the quarter, compared to analysts' expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The firm's quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the company posted $6.10 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be issued a $0.47 dividend. The ex-dividend date is Friday, March 13th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.43. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.70%.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the sale, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. This represents a 1.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company's stock, valued at approximately $63,499,170. The trade was a 3.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on TMO shares. Evercore reaffirmed an "outperform" rating and set a $650.00 target price on shares of Thermo Fisher Scientific in a report on Monday, January 5th. UBS Group restated a "neutral" rating and set a $615.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. The Goldman Sachs Group assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, December 9th. They set a "buy" rating and a $685.00 price target on the stock. Robert W. Baird set a $653.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Finally, Wells Fargo & Company set a $683.00 target price on Thermo Fisher Scientific in a research note on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $633.68.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.